Press Releases Galecto, Inc.

Equities

GLTO

US36322Q1076

Real-time Estimate Cboe BZX Other stock markets 10:32:11 08/05/2024 pm IST			5-day change	1st Jan Change
0.7 ^USD	-1.42%		+4.40%	-1.39%

01/05	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI
29/04	Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	02/05	AQ
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis	22/12	AQ
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)	23/23/23	PU
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial	23/23/23	AQ
Galecto Announces Plans to Explore Strategic Alternatives	27/23/27	AQ
Galecto to Present at Investor Conferences in September	31/23/31	AQ
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis	15/23/15	AQ
Galecto Reports Second Quarter Operating and Financial Results	01/23/01	AQ
Galecto Set to Join Russell Microcap® Index	20/23/20	AQ
Galecto to Present at the Upcoming Jefferies Healthcare Conference	30/23/30	AQ
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis	23/23/23	AQ
Galecto : ATS 2023 poster - The Anti-Fibrotic Effect of GB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices from Idiopathic Pulmonary Fibrosis Tissue	22/23/22	PU
Galecto to Present Poster at Upcoming ATS 2023 International Conference	18/23/18	AQ
Galecto Reports First Quarter Operating and Financial Results	28/23/28	AQ
GALECTO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	28/23/28	AQ
Galecto to Present Two Posters at AACR Annual Meeting 2023	13/23/13	AQ
GALECTO, INC. : Regulation FD Disclosure (form 8-K)	11/23/11	AQ
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022	09/23/09	GL
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022	09/23/09	GL
GALECTO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	09/23/09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Galecto, Inc.

Equities

GLTO

US36322Q1076

Press Releases

Filters